Atara Biotherapeutics Plunges 16.09% Post Reverse Split

On July 31, 2025, Atara's stock experienced a significant drop of 16.09% in pre-market trading, indicating a notable shift in investor sentiment towards the biotechnology company.

Atara Biotherapeutics, Inc. recently underwent a 1 for 25 reverse stock split, which means shareholders now hold 1 share for every 25 shares they previously owned. This corporate action is often taken to boost the stock price and attract more investors, but it can also signal underlying financial challenges or strategic shifts within the company.

Despite the recent volatility, some analysts predict a potential rise in Atara's stock price over the next three months, with a 90% probability of holding a price between certain levels. This optimistic outlook suggests that the market may be anticipating positive developments or strategic moves from the company in the near future.